$AMIX: Jun/2026 Results

Autonomix Medical reports after close; focus on cash runway and procedural volume guidance.

Loading exclusive…

Key Points

No consensus EPS estimates; focus on cash and guidance.
Fiscal Q2 (Jun/2026) results report after close.
Commercial adoption of Sympathy platform is key metric.
Small-cap volatility expected due to low liquidity.

What To Watch

Cash position and burn rate update.
Procedural volume and hospital adoption metrics.
Management commentary on reimbursement and competition.
Any guidance on future capital raising needs.

Market Analysis

How the tape may move from the last update’s mark — not from the open, and not the session % already printed.

With no EPS consensus, the stock will trade on qualitative factors. Positive commercial traction or extended cash runway will drive upside, while any hint of dilution or stalled adoption will cause downside. The small market cap amplifies these moves.

Expected Move From Here -5.0% to +8.0% From last update, not from the open

Certainty 40%

Why

Low certainty due to lack of analyst estimates and low liquidity. The range is wide to account for potential binary outcomes based on management commentary. Small-cap medtechs often see exaggerated moves on earnings without clear consensus anchors.